Recent Updates
Recently added Catalysts
MBX

MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer

Tuesday, January 5, 2021 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+163%
120-day peak, hindsight
Typical move
5.3%
average across 7 past catalysts
Cash runway
~55 mo
Minimal dilution risk
Lead asset
MBX 4291
Phase 1 · Obesity

Full Press Release Details

MBX Biosciences Appoints Mary Jane Geiger, M.D., Ph.D., as Chief Medical Officer.
ShareAdd on Google
Tags: MBX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Jan 5, 2021

Biotech snapshot

Cash runway
$419M liquidity · $8M/mo burn
~55 mo
Minimal dilution risk
Lead asset
MBX 4291Phase 1
Obesity →

Catalyst track record

+163%
best trade around MBX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for MBX.

See every catalyst's timing & PoA →